Chapter 28
References
1. Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S, Tancini G, Tisi E, Archili C, De Toma D, Pipino G, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology. 1992;49(5):336-9.
Hawk ET, Viner JL. Statins in esophageal cancer cell lines: promising lead? Am J Gastroenterol. 2008 Apr;103(4):838-41.
Ogunwobi OO, Beales IL. Statins inhibit
proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Am J Gastroenterol. 2008 Apr;103(4):825-37.
3. Muck AO, Seeger H, Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther. 2004 Dec;42(12):695-700.
Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, Cummings SR, Bauer DC. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt). 2003 Oct;12(8):749-56.
Mueck AO, Seeger H, Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause. 2003 Jul-Aug;10(4):332-6.
Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis. 2001 Oct;22(10):1727-31.
Jánosi J, Sebestyén A, Bocsi J, Barna G, Nagy K, Vályi-Nagy I, Kopper L.
Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells. Anticancer Res. 2004 May-Jun;24(3a):1817-22.
Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol. 2003 Oct;23(4):1055-69.
Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7.
Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C, Emmerich B. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol. 2007 Sep;79(3):240-3.
Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001 Apr 6;84(7):886-91.
4. Reichle A, Bross K, Vogt T, Bataille F, Wild P, Berand A, Andreesen R. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer. 2004 Nov 15;101(10):2247-56.
5. Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose
interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced
antitumor immunity by blocking the opioid system. Neuroendocrinol Lett. 2002;
23(4):341-4.
Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G. A new
neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the
long-acting opioid antagonist naltrexone in metastatic cancer patients progressing
on interleukin-2 alone. Neuroendocrinol Lett. 2002; 23(3):255-8.
Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol. 2000
Nov;17(5):1053-61.
Berkson BM, Rubin DM, Berkson AJ. Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone. Integr Cancer Ther. 2007 Sep;6(3):293-6.
Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2006 Mar;5(1):83-9.
6. Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg. 2008 Aug;86(2):383-9;
Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, Teknos TN. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther. 2007 Mar;6(3):1039-45.
Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, Smith DC. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology. 2006;71(3-4):168-75.
Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review. Integr Cancer Ther. 2002 Dec;1(4):327-37.
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008 Jan 15;112(2):326-30.
Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res. 2006 Jul-Aug;26(4A):2647-51.
8. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, Kunze S, Schirrmacher V, Herold-Mende C. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol. 2004 Nov 1;22(21):4272-81.
9. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007 May 20;25(15):2078-85.
10. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008 Jan;179(1):53-6.
11. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008 Apr;222:357-68.
Odunsi K, Sabbatini P. Harnessing the immune system for ovarian cancer therapy.
Am J Reprod Immunol. 2008 Jan;59(1):62-74.
12. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007 May;59(6):795-805.
Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, Tornillo L, Terracciano L, Spichtin H, Mirlacher M, Simon R, Sauter G. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol. 2007 Feb;20(2):192-8.
13. Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res. 2005 Sep 15;11(18):6738-44.
Kim SO, Chun KS, Kundu JK, Surh YJ. Inhibitory effects of [6]-gingerol on PMA-induced COX-2 expression and activation of NF-kappaB and p38 MAPK in mouse skin.
Biofactors. 2004;21(1-4):27-31.
Szymczak M, Murray M, Petrovic N. Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood. 2008 Apr 1;111(7):3514-21.
Zhang DY, Wu J, Ye F, Xue L, Jiang S, Yi J, Zhang W, Wei H, Sung M, Wang W, Li X.
Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res. 2003 Jul 15;63(14):4037-43.
14. Schwarz S, Obermüller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK.
Lycopene inhibits disease progression in patients with benign prostate hyperplasia.
J Nutr. 2008 Jan;138(1):49-53.
Walfisch S, Walfisch Y, Kirilov E, Linde N, Mnitentag H, Agbaria R, Sharoni Y, Levy J.
Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. Eur J Cancer Prev. 2007 Aug;16(4):298-303.
Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr. 2003 Jul;133(7):2367-76.
Phan TT, See P, Tran E, Nguyen TT, Chan SY, Lee ST, Huynh H. Suppression of insulin-like growth factor signalling pathway and collagen expression in keloid-derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids. Br J Dermatol. 2003 Mar;148(3):544-52.
15. Plouzek CA,
Ciolino HP,
Clarke R,
Yeh GC. Inhibition of P-glycoprotein activity
and reversal of multidrug resistance in vitro by rosemary extract.
Eur J
Cancer. 1999 Oct;35(10):1541-5.
Sircar S,
Cai F,
Begin ME,
Weber JM. Transformation renders MDR cells more
sensitive to polyunsaturated fatty acids.
Anticancer Res. 1990 Nov-Dec;10(6):1783-6.
Arora A, Seth K, Kalra N, Shukla Y. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol. Toxicol Appl Pharmacol. 2005 Feb 1;202(3):237-43.
16. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C, Fotsis T.
Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res. 2004 Nov 1;64(21):7936-46.
Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X, Jiang BH. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis. 2007 Apr;28(4):858-64.
Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst. 2006 Jun 21;98(12):846-55.
17. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.
Oncogene. 2003 Jul 31;22(31):4851-9.
Kuo PL, Lin CC. Green tea constituent (-)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J Biomed Sci. 2003 Mar-Apr;10(2):219-27.
Yamasaki M, Fujita S, Ishiyama E, Mukai A, Madhyastha H, Sakakibara Y, Suiko M, Hatakeyama K, Nemoto T, Morishita K, Kataoka H, Tsubouchi H, Nishiyama K. Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo.
Cancer Sci. 2007 Nov;98(11):1740-6.
Ye R, Goodarzi AA, Kurz EU, Saito S, Higashimoto Y, Lavin MF, Appella E, Anderson CW, Lees-Miller SP. The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44.
18. Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene. 2006 Jan 12;25(2):278-87.
Stewart JR, Artime MC, O'Brian CA. Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr. 2003 Jul;133(7 Suppl):2440S-2443S.
Tyagi A, Agarwal R, Agarwal C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene. 2003 Mar 6;22(9):1302-16.
19. Singh SV, Mohan RR, Agarwal R, Benson PJ, Hu X, Rudy MA, Xia H, Katoh A, Srivastava SK, Mukhtar H, Gupta V, Zaren HA. Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-RAS oncogene transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Biochem Biophys Res Commun. 1996 Aug 14;225(2):660-5.
Arora A, Kalra N, Shukla Y. Regulation of p21/ras protein expression by diallyl sulfide in DMBA induced neoplastic changes in mouse skin. Cancer Lett. 2006 Oct 8;242(1):28-36.
Asamoto M, Ota T, Toriyama-Baba H, Hokaiwado N, Naito A, Tsuda H. Mammary carcinomas induced in human c-Ha-ras proto-oncogene transgenic rats are estrogen-independent, but responsive to d-limonene treatment. Jpn J Cancer Res. 2002 Jan;93(1):32-5.
Yano Y, Satoh H, Fukumoto K, Kumadaki I, Ichikawa T, Yamada K, Hagiwara K, Yano T. Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-alpha-tocotrienol, a redox-silent derivative of alpha-tocotrienol. Int J Cancer. 2005 Jul 10;115(5):839-46.
20. Shimizu M, Deguchi A, Joe AK, Mckoy JF, Moriwaki H, Weinstein IB. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol. 2005;5(1):69-78.
Masuda M, Suzui M, Lim JT, Weinstein IB. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res. 2003 Aug 15;9(9):3486-91.
Sant M, Allemani C, Sieri S, Krogh V, Menard S, Tagliabue E, Nardini E, Micheli A, Crosignani P, Muti P, Berrino F. Salad vegetables dietary pattern protects against HER-2-positive breast cancer: a prospective Italian study. Int J Cancer. 2007 Aug 15;121(4):911-4.
Menendez JA, Vellon L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol. 2005 Mar;16(3):359-71.
21. Qi M, Anderson AE, Chen DZ, Sun S, Auborn KJ. Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Mol Med. 2005 Jan-Dec;11(1-12):59-63.
Cao F, Jin TY, Zhou YF. Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene. Biomed Environ Sci. 2006 Feb;19(1):35-41.
nbsp;
22.
Grossarth-Maticek R,
Ziegler R.
Prospective controlled cohort
studies on long-term therapy of breast cancer patients with a mistletoe
preparation (Iscador(r).
Forsch
Komplementarmed. 2006 Oct;13(5):285-92.
Büssing A. Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
Arzneimittelforschung. 2006 Jun;56(6A):508-15.
Urech K,
Buessing A,
Thalmann G,
Schaefermeyer H,
Heusser P.
Antiproliferative effects of mistletoe
(Viscum album L.) extract in urinary bladder carcinoma cell lines.
Anticancer Res. 2006 Jul-Aug;26(4B):3049-55.
Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer. 2003 Nov 1;107(2):262-7.
Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003297.
Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007 Mar 26;12(3):103-19
23. Ernst E, Schmidt K. Ukrain - a new cancer cure? A systematic review of randomised clinical trials. BMC Cancer. 2005 Jul 1;5:69.
Zemskov V, Prokopchuk O, Susak Y, Zemskov S, Tkachenko O, Hodysh Y, Nowicky W. Efficacy of ukrain in the treatment of pancreatic cancer. Langenbecks Arch Surg. 2002; 387(2):84-9.
24.
Padayatty SJ,
Riordan HD,
Hewitt SM,
Katz A,
Hoffer LJ,
Levine M.
Intravenously administered vitamin C as
cancer therapy: three cases.
CMAJ. 2006 Mar
28;174(7):937-42.
Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E,
Levine M. Pharmacologic ascorbic acid
concentrations selectively kill cancer cells: action as a pro-drug to deliver
hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13604-9.
Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M.
Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004 Apr 6;140(7):533-7.
Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo.
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8749-54.
Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008 Jun 25. [Epub ahead of print]
25.
Jakab F, Mayer A, Hoffmann A, Hidvegi M.
First clinical data of a natural immunomodulator in colorectal cancer.
Hepatogastroenterology. 2000 Mar-Apr;47(32):393-5.
Hidvegi M, Raso E, Tomoskozi-Farkas R, Szende B,
Paku S, Pronai L, Bocsi J, Lapis K.
MSC, a new benzoquinone-containing natural product with antimetastatic effect.
Cancer Biother Radiopharm. 1999 Aug;14(4):277-89.
Zalatnai A, Lapis K, Szende B, Raso E, Telekes A, Resetar A, Hidvegi M.
Wheat germ extract inhibits
experimental colon carcinogenesis in F-344 rats. Carcinogenesis. 2001
Oct;22(10):1649-52.
Jakab F, Shoenfeld Y, Balogh A, Nichelatti M,
Hoffmann A, Kahan Z, Lapis K, Mayer A, Sapy P, Szentpetery F, Telekes A, Thurzo
L, Vagvolgyi A, Hidvegi M. A
medical nutriment has supportive value in the treatment of colorectal cancer. Br
J Cancer. 2003 Aug 4;89(3):465-9.
26.
Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM.
Phase 1
trial of Anvirzel in patients with refractory solid tumors.
Invest New Drugs. 2006 Sep;24(5):423-7.
Newman RA, Kondo Y, Yokoyama T, Dixon S,
Cartwright C, Chan D, Johansen M, Yang P.
Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a
lipid-soluble cardiac glycoside. Integr
Cancer Ther. 2007 Dec;6(4):354-64.
27. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006 Jan 20;24(3):419-30.
Xu L, Lao LX, Ge A, Yu S, Li J, Mansky PJ. Chinese herbal medicine for cancer pain.
Integr Cancer Ther. 2007 Sep;6(3):208-34.
Shu X, McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integr Cancer Ther. 2005 Sep;4(3):219-29.